<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04530734</url>
  </required_header>
  <id_info>
    <org_study_id>2018_17</org_study_id>
    <secondary_id>2019-A01208-49</secondary_id>
    <nct_id>NCT04530734</nct_id>
  </id_info>
  <brief_title>Blood Concentration in Lorazepam and Treatment in Adult Catatonia</brief_title>
  <acronym>PHARMAPREDICAT</acronym>
  <official_title>Blood Concentration in Lorazepam and Treatment in Adult Catatonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Catatonia is a severe form of psychomotor disturbance with a heterogenous presentation. It&#xD;
      affects approximately 10% of acute psychiatric inpatients. According to the fifth edition of&#xD;
      DSM-5 the diagnosis of catatonia can be made when three or more symptoms from the twelve&#xD;
      following are present : catalepsy, waxy flexibility, stupor, agitation, mutism, negativism,&#xD;
      posturing, mannerisms, stereotypies, grimacing, echolalia, echopraxia. It can occur in&#xD;
      various psychiatric diseases, including mood disorders or schizophrenia, but also in various&#xD;
      non-psychiatric disorders [metabolic disturbances, viral infections (including HIV), typhoid&#xD;
      fever, heat stroke, and autoimmune disease].&#xD;
&#xD;
      Benzodiazepines, especially LORAZEPAM, are the most common initial treatment, with a&#xD;
      remission rate of approximately 70-80 %, regardless of the cause or the clinical&#xD;
      manifestations. This first line treatment is titrated gradually according to the therapeutic&#xD;
      response over a few days up to 20-25 mg per day. Electroconvulsive therapy (ECT) is initiated&#xD;
      on patients with catatonia who do not respond to benzodiazepines.&#xD;
&#xD;
      Interestingly, pharmacogenetic variants can alter the metabolism of lorazepam (e.g., the&#xD;
      UGT2B15 * 2 allele slows it down).&#xD;
&#xD;
      The main objective of this study is to assess the link between clinical response to&#xD;
      lorazepam, residual plasma concentrations of lorazepam after 72 hours of fixed dosage, and&#xD;
      the existence of genetic polymorphisms modifying the metabolism of lorazepam. Our hypothesis&#xD;
      is that non-responding patients have lowered blood concentrations of lorazepam associated to&#xD;
      a genetic profile of rapid metabolism. Evaluating the predictive factors of the response to&#xD;
      treatment would allow early and precise identification of non-responder patients in order to&#xD;
      adapt their first-line treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentrations of lorazepam measured after 72 hours of treatment with lorazepam at fixed dose</measure>
    <time_frame>at 72 hours of treatment with lorazepam</time_frame>
    <description>Compare the residual plasma concentration of lorazepam after 72 hours of taking fixed-dose lorazepam between responder and non-responder patients defined by the persistence of this diagnosis despite a daily dosage of 24 mg of lorazepam for 72 hours</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Catatonia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA from blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        102 patients with catatonia. 70 responder patients, 32 non responder&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  catatonia according DSM-5&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is less than 18 years of age&#xD;
&#xD;
          -  Subject is pregnant at the time of the study&#xD;
&#xD;
          -  Subject/legal guardian unwilling to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali AMAD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ali AMAD, MD</last_name>
    <phone>03 20 44 44 60</phone>
    <phone_ext>+33</phone_ext>
    <email>ali.amad@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>HÃ´pital Fontan, CHU lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0320445962</phone>
    </contact>
    <investigator>
      <last_name>Ali Amad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 25, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>September 17, 2020</last_update_submitted>
  <last_update_submitted_qc>September 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Catatonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

